Email this article Clovate therapy of steroid-sensitive dermatoses
- Authors: Snarskaya E.S.1, Shnakhova L.M1
-
Affiliations:
- I.M. Setchenov First Moscow State Medical University
- Issue: Vol 17, No 6 (2014)
- Pages: 18-21
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/36906
- DOI: https://doi.org/10.17816/dv36906
- ID: 36906
Cite item
Full Text
Abstract
The choice of a topical corticosteroid drug is a difficult problem for practical physician. Modern topical glucocorticosteroids are the most effective, as they unite the positive characteristics of previous drugs, their activity is comparable to that of fluorinated glucocorticoids, and their untoward effects (characteristic of hydrocortisone acetate) are the minimum. It is a class of modern potent drugs. One of them is Clovate® (active substance 0.05% clobethasol propionate; "Valeant", Canada). Prescription of a short course of Clovate during exacerbation and progress of severe psoriasis forms is safe and not associated with subclinical signs of augmenting adrenosuppression. "Step-down" therapy leads to a rapid clinical effect without side effects. Experience gained in the use of this method is presented.
Full Text
##article.viewOnOriginalSite##About the authors
Elena S. Snarskaya
I.M. Setchenov First Moscow State Medical University
Email: snarskaya-dok@mail.ru
MD, PhD, DSc, prof. 119991, Moscow, Russia
L. M Shnakhova
I.M. Setchenov First Moscow State Medical UniversityКафедра кожных и венерических болезней ИПО; ассистент 119991, Moscow, Russia
References
- Sterry W., Asadullah K. Topical glucocorticoid therapy in dermatology. Ernst. Schering Res. Found Workshop. 2002; 40: 39-54.
- Pearce D.J., Stealey K.H., Balkrishnan R., Fleischer A.B. Jr., Feldman S.R. Psoriasis treatment in the United Stated at the end of the 20th century. Int. J. Dermatol. 2006; 45(4): 370-4.
- Белоусова Т.А. Рациональное применение наружных глюкокортикостероидов в общей клинической практике. Русский медицинский журнал. 2006; 29: 2090-4.
- Короткий Н.Г., Гамаюнов Б.Н., Тихомиров А.А. Практика применения новых наружных средств в лечении атопического дерматита. Клиническая дерматология и венерология. 2010; 1: 61-6.
- Бакулев А.Л., Кравченя С.С. Об эффективности и безопасности применения клобетазола пропионата коротким курсом у больных псориазом в фазе прогрессирования. Вестник дерматологии и венерологии. 2012; 3: 121-5.
- Пинегин Б.В., Иванов О.Л., Пинегин В.Б. Роль клеток иммунной системы и цитокинов в развитии псориаза. Роcсийский журнал кожных и венерических болезней. 2013; 3: 19-24.
- Хлебникова А.Н. Современные подходы к наружной терапии псориаза. Вестник дерматологии и венерологии. 2012; 1: 87-8.
- Castela E.L., Archier J.V., Devaux S., Gallini A., Aractingi S., Cribier B., et al. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal suppression and skin atrophy. J. Eur. Acad. Dermatol. Venerol. 2012; 26(Suppl. 3): 47-51. doi: 10.1111/j.1468-3083.2012.04523.x.
- Weston W.L., Fennessey P.V., Morelli J.V., Schwab H., Mooney J., Samson C., et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J. Invest. Dermatol. 1988; 90(4): 532-5.
